{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T06:58:11Z","timestamp":1793084291017,"version":"4.5.0"},"reference-count":65,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2020,11,5]],"date-time":"2020-11-05T00:00:00Z","timestamp":1604534400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,11,5]],"date-time":"2020-11-05T00:00:00Z","timestamp":1604534400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Acta Pharmacol Sin"],"published-print":{"date-parts":[[2021,8]]},"DOI":"10.1038\/s41401-020-00553-9","type":"journal-article","created":{"date-parts":[[2020,11,5]],"date-time":"2020-11-05T03:04:24Z","timestamp":1604545464000},"page":"1212-1222","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":73,"title":["Tu-San-Qi (Gynura japonica): the culprit behind pyrrolizidine alkaloid-induced liver injury in China"],"prefix":"10.1038","volume":"42","author":[{"given":"Lin","family":"Zhu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chun-yuan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong-ping","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hu-biao","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiang","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji-yao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter P.","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ge","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,11,5]]},"reference":[{"key":"553_CR1","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1038\/ajg.2014.131","volume":"109","author":"NP Chalasani","year":"2014","unstructured":"Chalasani NP, Hayashi PH, Bonkovsky HL, Herbert L, Navarro VJ, Lee WM, et al. ACG clinical guideline: the diagnosis and management of idiosyncratic drug-induced liver injury. Am J Gastroenterol. 2014;109:950\u201366.","journal-title":"Am J Gastroenterol"},{"key":"553_CR2","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1038\/nrd1750","volume":"4","author":"N Kaplowitz","year":"2005","unstructured":"Kaplowitz N. Idiosyncratic drug hepatotoxicity. Nat Rev Drug Discov. 2005;4:489\u201399.","journal-title":"Nat Rev Drug Discov"},{"key":"553_CR3","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1056\/NEJMra052270","volume":"354","author":"VJ Navarro","year":"2006","unstructured":"Navarro VJ, Senior JR. Drug-related hepatotoxicity. N. Engl J Med. 2006;354:731\u20139.","journal-title":"N. Engl J Med"},{"key":"553_CR4","doi-asserted-by":"publisher","first-page":"2230","DOI":"10.1053\/j.gastro.2019.02.002","volume":"156","author":"T Shen","year":"2019","unstructured":"Shen T, Liu YX, Shang J, Xie Q, Li J, Yan M, et al. Incidence and etiology of drug-induced liver injury in mainland China. Gastroenterology. 2019;156:2230\u201341.","journal-title":"Gastroenterology."},{"key":"553_CR5","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1016\/j.clinre.2016.01.006","volume":"40","author":"DC Valla","year":"2016","unstructured":"Valla DC, Cazals-Hatem D. Sinusoidal obstruction syndrome. Clin Res Hepatol Gastroenterol. 2016;40:378\u201385.","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"553_CR6","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1186\/s12876-018-0879-7","volume":"18","author":"Y Wang","year":"2018","unstructured":"Wang Y, Qiao D, Li Y, Xu F. Risk factors for hepatic veno-occlusive disease caused by Gynura segetum: a retrospective study. BMC Gastroenterol. 2018;18:156.","journal-title":"BMC Gastroenterol"},{"key":"553_CR7","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1111\/1751-2980.12112","volume":"15","author":"JY Wang","year":"2014","unstructured":"Wang JY, Gao H. Tusanqi and hepatic sinusoidal obstruction syndrome. J Dig Dis. 2014;15:105\u20137.","journal-title":"J Dig Dis"},{"key":"553_CR8","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1021\/tx500403t","volume":"28","author":"JA Edgar","year":"2015","unstructured":"Edgar JA, Molyneux RJ, Colegate SM. Pyrrolizidine alkaloids: potential role in the etiology of cancers, pulmonary hypertension, congenital anomalies, and liver disease. Chem Res Toxicol. 2015;28:4\u201320.","journal-title":"Chem Res Toxicol"},{"key":"553_CR9","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1016\/j.jhep.2010.07.031","volume":"54","author":"G Lin","year":"2011","unstructured":"Lin G, Wang JY, Li N, Li M, Gao H, Ji Y, et al. Hepatic sinusoidal obstruction syndrome associated with consumption of Gynura segetum. J Hepatol. 2011;54:666\u201373.","journal-title":"J Hepatol"},{"key":"553_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1081\/DMR-120028426","volume":"36","author":"PP Fu","year":"2004","unstructured":"Fu PP, Xia QS, Lin G, Chou MW. Pyrrolizidine alkaloids\u2013genotoxicity, metabolism enzymes, metabolic activation, and mechanisms. Drug Metab Rev. 2004;36:1\u201355.","journal-title":"Drug Metab Rev"},{"key":"553_CR11","unstructured":"Mattocks AR. Chemistry and toxicology of pyrrolizidine alkaloids. London: Academic Press; 1986."},{"key":"553_CR12","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1021\/np50014a001","volume":"44","author":"LW Smith","year":"1981","unstructured":"Smith LW, Culvenor CC. Plant sources of hepatotoxic pyrrolizidine alkaloids. J Nat Prod. 1981;44:129\u201352.","journal-title":"J Nat Prod"},{"key":"553_CR13","doi-asserted-by":"publisher","first-page":"313280","DOI":"10.1155\/2010\/313280","volume":"2010","author":"F Kakar","year":"2010","unstructured":"Kakar F, Akbarian Z, Leslie T, Mustafa ML, Watson J, Egmond HPV, et al. An outbreak of hepatic veno-occlusive disease in western Afghanistan associated with exposure to wheat flour contaminated with pyrrolizidine alkaloids. J Toxicol. 2010;2010:313280.","journal-title":"J Toxicol"},{"key":"553_CR14","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1021\/bk-2000-0745.ch008","volume":"8","author":"JA Edgar","year":"1999","unstructured":"Edgar JA, Smith LW. Transfer of pyrrolizidine alkaloids into eggs: food safety implications. ACS Symp Ser. 1999;8:118\u201328.","journal-title":"ACS Symp Ser"},{"key":"553_CR15","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1002\/mnfr.200900289","volume":"54","author":"M Kempf","year":"2010","unstructured":"Kempf M, Heil S, Hasslauer I, Schmidt L, Ohe Kvd, Theuring C, et al. Pyrrolizidine alkaloids in pollen and pollen products. Mol Nutr Food Res. 2010;54:292\u2013300.","journal-title":"Mol Nutr Food Res"},{"key":"553_CR16","doi-asserted-by":"publisher","first-page":"892","DOI":"10.2527\/1990.683892x","volume":"68","author":"KE Panter","year":"1990","unstructured":"Panter KE, James LF. Natural plant toxicants in milk: a review. J Anim Sci. 1990;68:892\u2013904.","journal-title":"J Anim Sci"},{"key":"553_CR17","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1016\/S0140-6736(01)00020-4","volume":"2","author":"FC Willmot","year":"1920","unstructured":"Willmot FC, Robertson GW. Senecio disease or cirrhosis of the liver due to Senecio poisoning. Lancet. 1920;2:848.","journal-title":"Lancet."},{"key":"553_CR18","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1021\/acs.chemrestox.8b00369","volume":"32","author":"J Ma","year":"2019","unstructured":"Ma J, Ruan J, Chen X, Li D, Yao S, Fu PP, et al. Pyrrole-hemoglobin adducts, a more feasible potential biomarker of pyrrolizidine alkaloid exposure. Chem Res Toxicol. 2019;32:1027\u201339.","journal-title":"Chem Res Toxicol"},{"key":"553_CR19","first-page":"1627","volume":"33","author":"Cooperative Group for Health and Gall Diseases, Chinese Society of Gastroenterology, Chinese Medical Association.","year":"2017","unstructured":"Cooperative Group for Health and Gall Diseases, Chinese Society of Gastroenterology, Chinese Medical Association. Expert consensus on diagnosis and treatment of pyrrolizidine alkaloids-related sinusoidal obstruction syndrome (2017, Nanjing). J Clin Hepatol. 2017;33:1627\u201337.","journal-title":"J Clin Hepatol."},{"key":"553_CR20","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1080\/10590501.2015.1096882","volume":"33","author":"JQ Ruan","year":"2015","unstructured":"Ruan JQ, Gao H, Li N, Xue JY, Chen J, Ke CQ, et al. Blood pyrrole-protein adducts-a biomarker of pyrrolizidine alkaloid-induced liver injury in humans. J Environ Sci Health C Environ Carcinog Ecotoxicol Rev.\u00a02015;33:404\u201321.","journal-title":"J Environ Sci Health C Environ Carcinog Ecotoxicol Rev."},{"key":"553_CR21","doi-asserted-by":"publisher","first-page":"3913","DOI":"10.1007\/s00204-017-2013-y","volume":"91","author":"MB Yang","year":"2017","unstructured":"Yang MB, Ruan JQ, Gao H, Li N, Ma J, Xue JY, et al. First evidence of pyrrolizidine alkaloid N-oxide-induced hepatic sinusoidal obstruction syndrome in humans. Arch Toxicol. 2017;91:3913\u20132925.","journal-title":"Arch Toxicol"},{"key":"553_CR22","doi-asserted-by":"publisher","first-page":"e942","DOI":"10.1097\/MD.0000000000000942","volume":"94","author":"XX Wang","year":"2015","unstructured":"Wang XX, Qi XS, Guo XZ. Tusanqi-related sinusoidal obstruction syndrome in China: a systematic review of the literatures. Medicine. 2015;94:e942.","journal-title":"Medicine"},{"key":"553_CR23","unstructured":"Commission of Chinese Materia Medica. Materia Medica of China. Shanghai (China): Shanghai Scientific and Technical Publishers; 1999a; 3: p 765\u20137."},{"key":"553_CR24","unstructured":"Commission of Chinese Materia Medica. Materia Medica of China. Shanghai (China): Shanghai Scientific and Technical Publishers; 1999b; 5: p 839\u201350."},{"key":"553_CR25","unstructured":"Commission of Chinese Materia Medica. Materia Medica of China. Shanghai (China): Shanghai Scientific and Technical Publishers; 1999c; 7: p 855\u20137."},{"key":"553_CR26","unstructured":"Flora of China Editorial Committee. Beijing (China): Flora of China. Science Press; 1999a; 78: p 128."},{"key":"553_CR27","unstructured":"Flora of China Editorial Committee. Beijing (China): Flora of China. Science Press; Flora of China. Science Press; 1999b; 78: p 312\u20133."},{"key":"553_CR28","unstructured":"Gynura japonica (Thunb.) Juel. World Flora Online. 2020. http:\/\/www.worldfloraonline.org\/taxon\/wfo-0000011089."},{"key":"553_CR29","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.phymed.2018.06.015","volume":"54","author":"AZ Xiong","year":"2019","unstructured":"Xiong AZ, Shao YL, Fang LX, Yang X, Zhang SC, Zheng J, et al. Comparative analysis of toxic components in different medicinal parts of Gynura japonica and its toxicity assessment on mice. Phytomedicine. 2019;54:77\u201388.","journal-title":"Phytomedicine."},{"key":"553_CR30","first-page":"187","volume":"19","author":"JG Hou","year":"1980","unstructured":"Hou JG. Veno-occlusive disease of the liver with report of 2 cases. Zhonghua Nei Ke Za Zhi. 1980;19:187\u201391.","journal-title":"Zhonghua Nei Ke Za Zhi"},{"key":"553_CR31","first-page":"636","volume":"33","author":"M Zhang","year":"2013","unstructured":"Zhang M, Zhuge YZ, Chen J. Hepatic venous pressure gradient and transjugular liver biopsy confirms a case of atypical hepatic venoocclusive disease. Chin J Gastroenterol. 2013;33:636\u20137.","journal-title":"Chin J Gastroenterol"},{"key":"553_CR32","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1111\/jgh.14612","volume":"34","author":"YZ Zhuge","year":"2019","unstructured":"Zhuge YZ, Liu YL, Xie WF, Zou XP, Xu JM, Wang JY, et al. Expert consensus on the clinical management of pyrrolizidine alkaloid-induced hepatic sinusoidal obstruction syndrome. J Gastroenterol Hepatol. 2019;34:634\u201342.","journal-title":"J Gastroenterol Hepatol"},{"key":"553_CR33","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1038\/sj.bmt.1705896","volume":"41","author":"AA Beihany","year":"2008","unstructured":"Beihany AA, Omar HA, Sahovic E, Chaudhri N, Mohareb FA, Sharif FA, et al. Successful treatment of hepatic veno-occlusive disease after myeloablative allogeneic hematopoietic stem cell transplantation by early administration of a short course of methylprednisolone. Bone Marrow Transpl. 2008;41:287\u201391.","journal-title":"Bone Marrow Transpl"},{"key":"553_CR34","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1111\/j.1440-1746.2009.05795.x","volume":"24","author":"M Narita","year":"2009","unstructured":"Narita M, Hatano E, Tamaki N, Yamanaka K, Yanagida A, Nagata H, et al. Dai-kenchu-to attenuates rat sinusoidal obstruction syndrome by inhibiting the accumulation of neutrophils in the liver. J Gastroenterol Hepatol. 2009;24:1051\u20137.","journal-title":"J Gastroenterol Hepatol"},{"key":"553_CR35","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1111\/j.1872-034X.2011.00830.x","volume":"41","author":"HY Zhu","year":"2011","unstructured":"Zhu HY, Chu Y, Huo JR, Chen Z, Yang L. Effect of prednisone on transforming growth factor-\u03b21, connective tissue growth factor, nuclear factor-\u03baB p65 and tumor necrosis factor-\u03b1 expression in a murine model of hepatic sinusoidal obstruction syndrome induced by Gynura segetum. Hepatol Res. 2011;41:795\u2013803.","journal-title":"Hepatol Res."},{"key":"553_CR36","doi-asserted-by":"publisher","first-page":"1867","DOI":"10.1111\/liv.13684","volume":"38","author":"YZ Zhuge","year":"2018","unstructured":"Zhuge YZ, Wang Y, Zhang F, Zhu CK, Zhang W, Zhang M, et al. Clinical characteristics and treatment of pyrrolizidine alkaloid-related hepatic vein occlusive disease. Liver Int. 2018;38:1867\u201374.","journal-title":"Liver Int"},{"key":"553_CR37","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.1002\/hep.22772","volume":"49","author":"LD Deleve","year":"2009","unstructured":"Deleve LD, Valla DC, Garcia-Tsao G. Vascular disorders of the liver. Hepatology. 2009;49:1729\u201364.","journal-title":"Hepatology."},{"key":"553_CR38","first-page":"536","volume":"81","author":"J Rubia","year":"1996","unstructured":"Rubia J, Carral A, Montes H, Urquijo JJ, Sanz GF, Sanz MA. Successful treatment of hepatic veno-occlusive disease in a peripheral blood progenitor cell transplant patient with a transjugular intrahepatic portosystemic stent-shunt (TIPS). Haematologica. 1996;81:536\u20139.","journal-title":"Haematologica."},{"key":"553_CR39","doi-asserted-by":"publisher","first-page":"1469","DOI":"10.1136\/gut.2007.133637","volume":"57","author":"DC Valla","year":"2008","unstructured":"Valla DC. Budd-Chiari syndrome and veno-occlusive disease\/sinusoidal obstruction syndrome. Gut. 2008;57:1469\u201378.","journal-title":"Gut."},{"key":"553_CR40","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1586\/ehm.12.18","volume":"5","author":"S Corbacioglu","year":"2012","unstructured":"Corbacioglu S, Kernan N, Lehmann L, Brochstein J, Revta C, Grupp S, et al. Defibrotide for the treatment of hepatic veno-occlusive disease in children after hematopoietic stem cell transplantation. Expert Rev Hematol. 2012;5:291\u2013302.","journal-title":"Expert Rev Hematol"},{"key":"553_CR41","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1111\/bjh.12558","volume":"163","author":"FL Dignan","year":"2013","unstructured":"Dignan FL, Wynn RF, Hadzic N, Karani J, Quaglia A, Pagliuca A, et al. BCSH\/BSBMT guideline: diagnosis and management of veno-occlusive disease (sinusoidal obstruction syndrome) following haematopoietic stem cell transplantation. Br J Haematol. 2013;163:444\u201357.","journal-title":"Br J Haematol"},{"key":"553_CR42","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1038\/sj.bmt.1705899","volume":"41","author":"VT Ho","year":"2008","unstructured":"Ho VT, Revta C, Richardson PG. Hepatic veno-occlusive disease after hematopoietic stem cell transplantation: update on defibrotide and other current investigational therapies. Bone Marrow Transpl. 2008;41:229\u201337.","journal-title":"Bone Marrow Transpl"},{"key":"553_CR43","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1002\/pca.1079","volume":"19","author":"Y Cao","year":"2008","unstructured":"Cao Y, Colegate SM, Edgar JA. Safety assessment of food and herbal products containing hepatotoxic pyrrolizidine alkaloids: interlaboratory consistency and the importance of N-oxide determination. Phytochem Anal. 2008;19:526\u201333.","journal-title":"Phytochem Anal"},{"key":"553_CR44","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1080\/19440049.2010.547519","volume":"28","author":"RJ Molyneux","year":"2011","unstructured":"Molyneux RJ, Gardner DL, Colegate SM, Edgar JA. Pyrrolizidine alkaloid toxicity in livestock: a paradigm for human poisoning? Food Addit Contam Part A Chem Anal Control Expo Risk Assess. 2011;28:293\u2013307.","journal-title":"Food Addit Contam Part A Chem Anal Control Expo Risk Assess"},{"key":"553_CR45","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1002\/pca.1314","volume":"22","author":"MT Williams","year":"2011","unstructured":"Williams MT, Warnock BJ, Betz JM, Beck JJ, Gardner DR, Lee ST, et al. Detection of high levels of pyrrolizidine-N-oxides in the endangered plant Cryptantha crassipes (Terlingua Creek cat\u2019s-eye) using HPLC-ESI-MS. Phytochem Anal. 2011;22:532\u201340.","journal-title":"Phytochem Anal"},{"key":"553_CR46","doi-asserted-by":"publisher","first-page":"2719","DOI":"10.1021\/jf0114482","volume":"50","author":"JA Edgar","year":"2002","unstructured":"Edgar JA, Roeder E, Molyneux RJ. Honey from plants containing pyrrolizidine alkaloids: a potential threat to health. J Agric Food Chem. 2002;50:2719\u201330.","journal-title":"J Agric Food Chem"},{"key":"553_CR47","first-page":"400","volume":"15","author":"PP Fu","year":"2007","unstructured":"Fu PP, Xia QS, Chou MW, Lin G. Detection, hepatotoxicity, and tumorigenicity of pyrrolizidine alkaloids in Chinese herbal plants and herbal dietary supplements. J Food Drug Anal. 2007;15:400\u201315.","journal-title":"J Food Drug Anal"},{"key":"553_CR48","first-page":"95","volume":"8","author":"BL Stegelmeier","year":"1999","unstructured":"Stegelmeier BL, Edgar JA, Colegate SM, Gardner DR, Schoch TK, Coulombe RA, et al. Pyrrolizidine alkaloid plants, metabolism and toxicity. J Nat Toxins. 1999;8:95\u2013116.","journal-title":"J Nat Toxins"},{"key":"553_CR49","doi-asserted-by":"publisher","first-page":"2197","DOI":"10.1007\/s00204-019-02499-2","volume":"93","author":"MB Yang","year":"2019","unstructured":"Yang MB, Ma J, Ruan JQ, Ye Y, Fu PP, Lin G. Intestinal and hepatic biotransformation of pyrrolizidine alkaloid N-oxides to toxic pyrrolizidine alkaloids. Arch Toxicol. 2019;93:2197\u2013209.","journal-title":"Arch Toxicol"},{"key":"553_CR50","doi-asserted-by":"publisher","first-page":"3403","DOI":"10.1007\/s00204-018-2309-6","volume":"92","author":"Y Lu","year":"2018","unstructured":"Lu Y, Ma J, Song ZJ, Ye Y, Fu PP, Lin G. The role of formation of pyrrole-ATP synthase subunit beta adduct in pyrrolizidine alkaloid-induced hepatotoxicity. Arch Toxicol. 2018;92:3403\u201314.","journal-title":"Arch Toxicol"},{"key":"553_CR51","doi-asserted-by":"publisher","first-page":"112421","DOI":"10.1016\/j.jep.2019.112421","volume":"249","author":"MB Yang","year":"2020","unstructured":"Yang MB, Ma J, Ruan JQ, Zhang CY, Ye Y, Fu PP, et al. Absorption difference between hepatotoxic pyrrolizidine alkaloids and their N-oxides-mechanism and its potential toxic impact. J Ethnopharmacol. 2020;249:112421.","journal-title":"J Ethnopharmacol"},{"key":"553_CR52","doi-asserted-by":"publisher","first-page":"4861","DOI":"10.2147\/DDDT.S87858","volume":"9","author":"H Gao","year":"2015","unstructured":"Gao H, Ruan JQ, Chen J, Li N, Ke CQ, Ye Y, et al. Blood pyrrole-protein adducts as a diagnostic and prognostic index in pyrrolizidine alkaloid-hepatic sinusoidal obstruction syndrome. Drug Des Devel Ther. 2015;9:4861\u20138.","journal-title":"Drug Des Devel Ther"},{"key":"553_CR53","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1111\/j.1751-2980.2011.00552.x","volume":"13","author":"H Gao","year":"2012","unstructured":"Gao H, Li N, Wang JY, Zhang SC, Lin G. Definitive diagnosis of hepatic sinusoidal obstruction syndrome induced by pyrrolizidine alkaloids. J Dig Dis. 2012;13:33\u201339.","journal-title":"J Dig Dis"},{"key":"553_CR54","doi-asserted-by":"publisher","first-page":"1222","DOI":"10.1016\/j.jhep.2019.02.014","volume":"70","author":"European Association for the Study of the Liver (EASL), Clinical Practice Guideline Panel.","year":"2019","unstructured":"European Association for the Study of the Liver (EASL), Clinical Practice Guideline Panel. EASL clinical practice guidelines: drug-induced liver injury. J Hepatol. 2019;70:1222\u201361.","journal-title":"J Hepatol"},{"key":"553_CR55","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40064-015-1600-8","volume":"4","author":"PC Ou","year":"2015","unstructured":"Ou PC, Chen Y, Li BZ, Zhang M, Liu XY, Li FF, et al. Causes, clinical features and outcomes of drug-induced liver injury in hospitalized patients in a Chinese tertiary care hospital. Springerplus. 2015;4:1\u20138.","journal-title":"Springerplus."},{"key":"553_CR56","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1007\/s12072-017-9793-2","volume":"11","author":"YC Yu","year":"2017","unstructured":"Yu YC, Mao YM, Chen CW, Chen JJ, Chen J, Cong WM, et al. CSH guidelines for the diagnosis and treatment of drug-induced liver injury. Hepatol Int. 2017;11:221\u201341.","journal-title":"Hepatol Int"},{"key":"553_CR57","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1878-5085-4-7","volume":"4","author":"E Drucker","year":"2013","unstructured":"Drucker E, Krapfenbauer K. Pitfalls and limitations in translation from biomarker discovery to clinical utility in predictive and personalised medicine. EPMA J. 2013;4:1\u201310.","journal-title":"EPMA J."},{"key":"553_CR58","doi-asserted-by":"publisher","first-page":"1482","DOI":"10.3389\/fphar.2019.01482","volume":"10","author":"L Meunier","year":"2019","unstructured":"Meunier L, Larrey D. Drug-induced liver injury: bomarkers, requirements, candidates, and validation. Front Pharmacol. 2019;10:1482.","journal-title":"Front Pharmacol."},{"key":"553_CR59","first-page":"1","volume":"9","author":"C Zhang","year":"2014","unstructured":"Zhang C, Jiang M, Zhang G, Bian ZX, Lu AP. Progress and perspectives of biomarker discovery in Chinese medicine research. Chin J Integr Med. 2014;9:1\u20139.","journal-title":"Chin J Integr Med"},{"key":"553_CR60","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1016\/j.jfda.2018.05.005","volume":"26","author":"J Ma","year":"2018","unstructured":"Ma J, Xia QS, Fu PP, Lin G. Pyrrole-protein adducts\u2013A biomarker of pyrrolizidine alkaloid-induced hepatotoxicity. J Food Drug Anal. 2018;26:965\u201372.","journal-title":"J Food Drug Anal"},{"key":"553_CR61","unstructured":"National Center for Environmental Health, 2012. https:\/\/www.cdc.gov\/nceh\/stories\/ethiopia.html"},{"key":"553_CR62","doi-asserted-by":"publisher","first-page":"1438","DOI":"10.1053\/j.gastro.2019.05.076","volume":"157","author":"WH Cong","year":"2019","unstructured":"Cong WH, Xin QQ, Gao YQ. RE: Incidence and etiology of drug-induced liver injury in mainland China. Gastroenterology. 2019;157:1438\u20139.","journal-title":"Gastroenterology."},{"key":"553_CR63","first-page":"762","volume":"46","author":"J Tang","year":"2011","unstructured":"Tang J, Hattori M. Pyrrolizidine alkaloids-containing Chinese medicines in the Chinese Pharmacopoeia and related safety concerns. Yao Xue Xue Bao. 2011;46:762\u201372.","journal-title":"Yao Xue Xue Bao"},{"key":"553_CR64","first-page":"198","volume":"10","author":"PP Fu","year":"2002","unstructured":"Fu PP, Yang YC, Xia QS, Chou MW, Cui YY, Lin G. Pyrrolizidine alkaloids-tumorigenic components in Chinese herbal medicines and dietary supplements. J Food Drug Anal. 2002;10:198\u2013211.","journal-title":"J Food Drug Anal"},{"key":"553_CR65","unstructured":"Chinese Pharmacopoeia Commission. Pharmacopoeia of the People\u2019s Republic of China. Beijing: Chinese Medical Science and Technology Press; Volume 1, 2015."}],"container-title":["Acta Pharmacologica Sinica"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41401-020-00553-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41401-020-00553-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41401-020-00553-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T17:02:49Z","timestamp":1684602169000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41401-020-00553-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,5]]},"references-count":65,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2021,8]]}},"alternative-id":["553"],"URL":"https:\/\/doi.org\/10.1038\/s41401-020-00553-9","relation":{},"ISSN":["1671-4083","1745-7254"],"issn-type":[{"value":"1671-4083","type":"print"},{"value":"1745-7254","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,5]]},"assertion":[{"value":"10 July 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 October 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 November 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}